同源康医药-B(02410.HK)在ESMO2025年会公布多项CDK抑制剂临床积极数据
TYK MEDICINESTYK MEDICINES(HK:02410) Ge Long Hui·2025-10-21 12:25

Core Insights - The company Tongyuan Kang Pharmaceutical-B (02410.HK) announced early clinical research results for three drugs in the cyclin-dependent kinase (CDK) inhibitor field, specifically TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] Group 1: Clinical Research - The early clinical research results were presented in poster format at the European Society for Medical Oncology (ESMO) annual meeting [1] - The ESMO 2025 annual meeting took place from October 17-21, 2025, in Berlin, Germany [1] - ESMO is recognized as one of the most influential academic events in the oncology field, attracting top experts and scholars [1]